Page 3 - Growth Factor News Today

Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for patients with advanced stages.

Supplementation with resistant starch leads to weight loss and improved insulin sensitivity by altering the gut microbiome and increasing secondary bile acids, according to a recent study in Nature Metabolism.

Scientists from Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago and colleagues found that an investigational protein replacement – recombinant human insulin-like growth factor 1 and its binding protein-3 (rhIGF-1/BP3) – protected neonatal mice from necrotizing enterocolitis (NEC), a deadly intestinal disease that often strikes extremely premature infants.

Boston College Assistant Professor of Biology Emrah Altindis has been awarded a five-year, $2.5-million grant from the National Institutes of Health to study viral insulins and mechanisms related to IGF-1 receptor protein inhibition and its potential applications in cancer treatment.

Injuries in the central nervous system heal poorly because cavities scar. Researchers hope to remedy this problem by filling the cavities in such a way that stem cells feel comfortable in them.

Researchers developed an artificial intelligence (AI)-based predictive system (AIPS) model for the early detection of lung cancer by combining radiological, clinical, and genetic data.

A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center.

Targeting senescent cells in the retina with a BCL-xL inhibitor shows promise as a durable treatment for diabetic macular edema, potentially offering long-term visual function improvements.

A single test to speed up diagnosis of a serious disease in pregnant women does not need to be repeated, new research has found.

Endothelial-mesenchymal transition (EndoMT, also termed as EndMT), a biological process resulting in the formation of mesenchymal (or lineage-committed) phenotypes from endothelial cells (lining blood vessels), plays a crucial role in tumor progression.